Fluorocholine

Summary

Fluorocholine (CHEMBL4303280) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 4
• Chemistry: 122.16 Da · C5H13FNO+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4303280
Name	Fluorocholine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	404592
Molecular formula	C5H13FNO+
Molecular weight	122.16
InChIKey	PBVFROWIWWGIFK-UHFFFAOYSA-N

SMILES: C[N+](C)(CCO)CF

IUPAC name: fluoromethyl-(2-hydroxyethyl)-dimethylazanium

Also known as: FLUOROCHOLINE CHLORIDE, Fluorocholine chloride

Parent form; salt/anhydrous children: CHEMBL5283705, CHEMBL5286912, CHEMBL5314939

Patent coverage: 45 distinct patent families (92 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	2
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02074202	PHASE3	UNKNOWN	To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma
NCT04965454	PHASE2	RECRUITING	Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
NCT01993160	Not specified	COMPLETED	18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer
NCT03105869	Not specified	COMPLETED	Repeatability of Positron Emission Tomography (TEP) With fluorométhyl-(18F)-diméthyl-2-hydroxyéthyl-ammonium

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).